engleski

Weekly vs. q3w docetaxel doses in patients with HRPC. NK cell activity data

Follow-up of HRPC patients treated with docetaxel combinations is obstracted by heterogeneity of bone scans and by the huge range of variations in the ability of such tumors to secrete PSA. Thus these parameters are rather difficult to use in monitoring the response of the therapy applied. We reported the use of Nk cell activity data, that indicate the presence of tumor cells in the circulation, as a valuable prognostic parameter that may be added to all others in the evaluation of the used treatment.

HRPC; docetaxel therapy; weekly and q3w; NK cell data as monitoring prognosticator

nije evidentirano